Fig. 4: Micro PK-PD monitoring of the anti-Parkinson's disease drug PPX. | Microsystems & Nanoengineering

Fig. 4: Micro PK-PD monitoring of the anti-Parkinson's disease drug PPX.

From: Micro pharmacokinetics-pharmacodynamics monitoring of anti-Parkinson’s disease drugs using a microphysiological BBB-brain organ-on-a-chip

Fig. 4

a Transwell model combined with LC-MS and electrochemical sensing technology to study micro pharmacokinetics of PPX. b Transwell model combined with LC-MS to study micro pharmacodynamics of PPX. Ctrl-1 group: After incubation with basic medium for 24 h, incubation with complete medium without PPX for 24 h; Ctrl-2 group: After incubation with basic medium containing 3 mM MPP+ for 24 h, incubation with complete medium without PPX for 24 h; Ctrl-3 group: After incubation with basic medium for 24 h, incubation with complete medium containing PPX for 24 h; Expl group: After incubation with basic medium containing 3 mM MPP+ for 24 h, incubation with complete medium containing PPX for 24 h. EC: Detection results of electrochemical sensors. c Photographs of the microfluidic device and the electrochemical sensing chip (magnified view). d Microfluidic organ-on-a-chip combined with LC-MS and electrochemical sensing technology to study micro pharmacokinetics of PPX. e Microfluidic organ-on-a-chip combined with LC-MS to study micro pharmacodynamics of PPX. f DPV curves of micro pharmacokinetics monitoring. Ctrl group: After culture with basic medium containing 3 mM MPP+ for 24 h, incubation with blank complete medium for 24 h; Expl group: After culture with basic medium containing 3 mM MPP+ for 24 h, incubation with complete medium containing PPX for 24 h

Back to article page